Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12138220 | 0.85 | SLC22A1 (0.44) | — | |
| SCHEMBL9411283 | 0.80 | GID4 (0.59) | KMT2AGID4OPRM1OPRK1SMPD1 | |
| SCHEMBL31569193 | 0.76 | CYP19A1 (0.36) | OPRM1OPRK1 | |
| SCHEMBL31569396 | 0.75 | CYP19A1 (0.38) | OPRM1 | |
| SCHEMBL31569143 | 0.75 | PRCP (0.39) | OPRM1 | |
| SCHEMBL6392691 | 0.73 | KMT2A (0.70) | KMT2ARAB9A | |
| SCHEMBL31568975 | 0.71 | SLC6A4 (0.44) | — | |
| SCHEMBL31569313 | 0.71 | SLC22A1 (0.61) | — | |
| SCHEMBL1364740 | 0.71 | KMT2A (0.40) | KMT2A | |
| SCHEMBL1364229 | 0.71 | KMT2A (0.40) | KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2144906-B1 | HETEROCYCLES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2144906-B1 | HETEROCYCLES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2144906-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008122513-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122513-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, HRH3 | KMT2A 817/4885GID4 921/4885OPRM1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.